ProteoTech, Inc.
12040 115th Ave., NE
Kirkland, WA 98034
Office: (425) 823-0400
Fax: (425) 823-8508
E-mail: info@proteotech.com
A World Leader in Therapeutics and
Diagnostics Targeting Amyloid Diseases
 |
|
Alan D. Snow, Ph.D., a former Research Associate Professor of Pathology at the University of Washington founded the Company in 1996 to accelerate new discoveries pertaining to proteoglycan technologies and their relationship to amyloid related diseases. Dr. Snow was one of the first researchers who identified that beta-amyloid protein should be a target for Alzheimer's disease therapeutics. His early research involved working with the Nobel Prize winner Dr. Stanley Prusiner on identifying the role of proteoglycans in prion diseases. Dr. Snow was the first researcher who identified the existence of specific proteoglycans in beta-amyloid protein deposits in Alzheimer's disease and Downs' Syndrome.
The Company has since been successful in independently discovering three proprietary classes of compounds that inhibit and disrupt the amyloid fibril process, which include: (1) unique small molecule compounds and analogs (representing new chemical entities), (2) unique small peptides (representing new chemical entities), and (3) small carbohydrates.
The Company believes that specific and newly identified compounds within these classes will lead to exciting new therapies for the treatment of amyloid diseases. ProteoTech's team of scientists is dedicated to improving the health of individuals targeted with these dreaded diseases. April, 2009 ProteoTech presents at the 11th annual C21 BioVentures Conference in Napa, California April, 2009 ProteoTech meets all scientific milestones for the Michael J. Fox foundation LEAPS award to continue development of Synuclere™ for treatment of Parkinson's disease. March 09, 2009 ProteoTech presents at 9th International Conference for Alzheimer's and Parkinson's Disease – Prague, Czech Republic, March 11-15, 2009 February 26, 2009 ProteoTech receives funding from The Michael J. Fox Foundation for Parkinson's Disease research to develop tools for imaging Alpha-Synuclein aggregation in living Parkinson's Brain December, 2008 ProteoTech's Alzheimer's Drug Exebryl-1® was featured in the Dec 2008 Issue of Reader's Digest November 11, 2008 ProteoTech presents at Rodman & Renshaw's 10th Annual Healthcare Conference August 07, 2008 ProteoTech's Exebryl-1® enters human clinical trials for the treatment of Alzheimer's Disease July 29, 2008 Exebryl-1® Phase I human clinical trial for Alzheimer's disease commences July 25, 2008 ProteoTech presents at International Alzheimer's Conference—Chicago, IL. May 28, 2008 ProteoTech receives clearance from FDA to proceed with Phase I human clinical trials for Exebryl-1® May 15, 2008 ProteoTech receives NIH SBIR Phase II continuation award for systemic amyloidosis therapeutic research April 28, 2008 ProteoTech files IND for Exebryl-1® for the treatment of mild-to-moderate Alzheimer's Disease |
 |
